Sector News

Novo Nordisk's North American head Jakob Riis to leave

March 3, 2017
Life sciences

Novo Nordisk Jakob Riis FalckNovo Nordisk’s head of North America Operations and president of Novo Nordisk Inc Jakob Riis has resigned.

He will remain with the Danish pharma company for a transitional period, ahead of joining Copenhagen-based health and safety services company Falck as president and CEO on 1 May.
Riis (pictured) joined Novo in 1996 and spent 10 years as the firm’s senior vice president of global marketing, during which he took on additional responsibilities in China and the Pacific region.

However, he only held his US role for seven months, and it will now by filled by Dough Langa, who currently serves as its US senior vice president for market access.

Göran Ando, chairman of Novo’s board of directors, said: “We are of course sad to see Jakob Riis leave. He has done a great job throughout his career in Novo Nordisk, and we wish him all the best.

“We welcome Doug Langa as our new head of North America operations. Doug’s experience in the US pharmaceutical market, his leadership skills and expertise in the area of market access make him the natural successor to Jakob Riis.”

Langa joined Novo in 2011 as senior director, managed markets, from GlaxoSmithKline where he was senior director of payer marketing and prior to that spent the majority of his career at Johnson & Johnson

Source: PMLive

comments closed

Related News

January 29, 2023

Colorcon, Inc. signs Put agreement with intent to acquire controlled atmosphere packaging specialist Airnov Healthcare Packaging

Life sciences

Airnov provides critical healthcare industries with high-quality, controlled atmosphere packaging, to protect their products from moisture and oxygen. The business has manufacturing facilities in the USA, France, China and India and employs around 700 people.

January 29, 2023

Takeda pledges up to $1.13B for rights to Hutchmed’s cancer drug fruquintinib outside of China

Life sciences

Takeda of Japan has partnered with Hong Kong-based Hutchmed, gaining the commercial rights to colorectal cancer drug fruquintinib outside of China for $400 million up front, plus $730 million in potential milestone payments. Takeda also will help develop fruquintinib, which can be applied to subtypes of refractory metastatic colorectal cancer, regardless of biomarker status, the companies said.

January 29, 2023

Vir taps Bayer dealmaker Marianne De Backer as its next CEO

Life sciences

On April 3, Scangos, who’s been chief executive officer at Vir since the start of 2017, will hand over the reins to Marianne De Backer, Ph.D. De Backer comes over from Bayer, where she currently heads up pharmaceutical strategy, business development and licensing. Alongside her CEO appointment, De Backer is set to join Vir’s board of directors, the company said Wednesday.

How can we help you?

We're easy to reach